371 related articles for article (PubMed ID: 21740524)
1. Deficiency in apolipoprotein E has a protective effect on diet-induced nonalcoholic fatty liver disease in mice.
Karavia EA; Papachristou DJ; Kotsikogianni I; Giopanou I; Kypreos KE
FEBS J; 2011 Sep; 278(17):3119-29. PubMed ID: 21740524
[TBL] [Abstract][Full Text] [Related]
2. Obesity potentiates development of fatty liver and insulin resistance, but not atherosclerosis, in high-fat diet-fed agouti LDLR-deficient mice.
Coenen KR; Hasty AH
Am J Physiol Endocrinol Metab; 2007 Aug; 293(2):E492-9. PubMed ID: 17566116
[TBL] [Abstract][Full Text] [Related]
3. Effect of macrophage-derived apolipoprotein E on hyperlipidemia and atherosclerosis of LDLR-deficient mice.
Shi W; Wang X; Wong J; Hedrick CC; Wong H; Castellani LW; Lusis AJ
Biochem Biophys Res Commun; 2004 Apr; 317(1):223-9. PubMed ID: 15047172
[TBL] [Abstract][Full Text] [Related]
4. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.
Jong MC; Dahlmans VE; van Gorp PJ; van Dijk KW; Breuer ML; Hofker MH; Havekes LM
J Clin Invest; 1996 Nov; 98(10):2259-67. PubMed ID: 8941642
[TBL] [Abstract][Full Text] [Related]
5. Urotensin II receptor knockout mice on an ApoE knockout background fed a high-fat diet exhibit an enhanced hyperlipidemic and atherosclerotic phenotype.
Bousette N; D'Orleans-Juste P; Kiss RS; You Z; Genest J; Al-Ramli W; Qureshi ST; Gramolini A; Behm D; Ohlstein EH; Harrison SM; Douglas SA; Giaid A
Circ Res; 2009 Sep; 105(7):686-95, 19 p following 695. PubMed ID: 19696412
[TBL] [Abstract][Full Text] [Related]
6. Opposing effects of apolipoprotein m on catabolism of apolipoprotein B-containing lipoproteins and atherosclerosis.
Christoffersen C; Pedersen TX; Gordts PL; Roebroek AJ; Dahlbäck B; Nielsen LB
Circ Res; 2010 May; 106(10):1624-34. PubMed ID: 20360257
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E predisposes to obesity and related metabolic dysfunctions in mice.
Karagiannides I; Abdou R; Tzortzopoulou A; Voshol PJ; Kypreos KE
FEBS J; 2008 Oct; 275(19):4796-809. PubMed ID: 18754772
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
[TBL] [Abstract][Full Text] [Related]
9. Microdispersed Oxidized Cellulose as a novel potential substance with hypolipidemic properties.
Jamborova G; Pospisilova N; Semecky V; Hyspler R; Ticha A; Pospechova K; Solichova D; Maxová M; Briestensky J; Real KJ; Nachtigal P
Nutrition; 2008; 24(11-12):1174-81. PubMed ID: 18640007
[TBL] [Abstract][Full Text] [Related]
10. Lack of phosphatidylethanolamine N-methyltransferase alters plasma VLDL phospholipids and attenuates atherosclerosis in mice.
Zhao Y; Su B; Jacobs RL; Kennedy B; Francis GA; Waddington E; Brosnan JT; Vance JE; Vance DE
Arterioscler Thromb Vasc Biol; 2009 Sep; 29(9):1349-55. PubMed ID: 19520976
[TBL] [Abstract][Full Text] [Related]
11. Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor.
Jong MC; van Dijk KW; Dahlmans VE; Van der Boom H; Kobayashi K; Oka K; Siest G; Chan L; Hofker MH; Havekes LM
Biochem J; 1999 Mar; 338 ( Pt 2)(Pt 2):281-7. PubMed ID: 10024503
[TBL] [Abstract][Full Text] [Related]
12. Harmful effects of increased LDLR expression in mice with human APOE*4 but not APOE*3.
Malloy SI; Altenburg MK; Knouff C; Lanningham-Foster L; Parks JS; Maeda N
Arterioscler Thromb Vasc Biol; 2004 Jan; 24(1):91-7. PubMed ID: 12969990
[TBL] [Abstract][Full Text] [Related]
13. Hepatic expression of apolipoprotein E inhibits progression of atherosclerosis without reducing cholesterol levels in LDL receptor-deficient mice.
Tsukamoto K; Tangirala RK; Chun S; Usher D; Puré E; Rader DJ
Mol Ther; 2000 Feb; 1(2):189-94. PubMed ID: 10933930
[TBL] [Abstract][Full Text] [Related]
14. Modulation of very low density lipoprotein production and clearance contributes to age- and gender- dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice.
van Vlijmen BJ; van 't Hof HB; Mol MJ; van der Boom H; van der Zee A; Frants RR; Hofker MH; Havekes LM
J Clin Invest; 1996 Mar; 97(5):1184-92. PubMed ID: 8636429
[TBL] [Abstract][Full Text] [Related]
15. Generation and characterization of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: Apob48-/-Lepob/ob mice devoid of ApoE or Ldlr.
Lloyd DJ; McCormick J; Helmering J; Kim KW; Wang M; Fordstrom P; Kaufman SA; Lindberg RA; Véniant MM
Am J Physiol Endocrinol Metab; 2008 Mar; 294(3):E496-505. PubMed ID: 18160459
[TBL] [Abstract][Full Text] [Related]
16. Intracellular localization and metabolism of chylomicron remnants in the livers of low density lipoprotein receptor-deficient mice and apoE-deficient mice. Evidence for slow metabolism via an alternative apoE-dependent pathway.
Mortimer BC; Beveridge DJ; Martins IJ; Redgrave TG
J Biol Chem; 1995 Dec; 270(48):28767-76. PubMed ID: 7499399
[TBL] [Abstract][Full Text] [Related]
17. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice.
Nachtigal P; Pospisilova N; Jamborova G; Pospechova K; Solichova D; Andrys C; Zdansky P; Micuda S; Semecky V
Life Sci; 2008 Mar; 82(13-14):708-17. PubMed ID: 18289605
[TBL] [Abstract][Full Text] [Related]
18. Effects of probucol on atherosclerosis of apoE-deficient or LDL receptor-deficient mice.
Yoshikawa T; Shimano H; Chen Z; Ishibashi S; Yamada N
Horm Metab Res; 2001 Aug; 33(8):472-9. PubMed ID: 11544561
[TBL] [Abstract][Full Text] [Related]
19. Dietary diacylglycerol extenuates arterial thrombosis in apoE and LDLR deficient mice.
Ijiri Y; Naemura A; Yamashita T; Meguro S; Watanabe H; Tokimitsu I; Yamamoto J
Thromb Res; 2006; 117(4):411-7. PubMed ID: 15885757
[TBL] [Abstract][Full Text] [Related]
20. Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice.
Mulvihill EE; Assini JM; Sutherland BG; DiMattia AS; Khami M; Koppes JB; Sawyez CG; Whitman SC; Huff MW
Arterioscler Thromb Vasc Biol; 2010 Apr; 30(4):742-8. PubMed ID: 20110573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
